Market Intelligence, Clinical Progress, and High-Purity Reagents for Inherited Retinal Dystrophy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CRB1 drug discovery and gene therapy validation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CRB1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation of EGF/LamG domains. |
View CRB1 Products |
| Gene Delivery | CRB1 Lentivirus Particles Full-length ORF (4.2 kb) with C-terminal tag for stable retinal cell line construction. Preserves ERLI PDZ-binding motif. |
View CRB1 Products |
| Benchmark Ab | Anti-CRB1 Recombinant Antibody Sequence-verified clone for apical localization and IF/IHC detection; human/mouse cross-reactive. |
View CRB1 Products |
| Validator | CRB1 siRNA Set For knockdown verification, specificity controls, and disease modeling in RPE cells. |
View CRB1 Products |
| Related Target A | CRB2 Crumbs homolog 2; functional paralog with compensatory mechanisms in retinal development. Critical for off-target counter-screening. |
View CRB2 Products |
| Related Target B | RPE65 Benchmark target for inherited retinal disease gene therapy. Used to standardize AAV delivery assessments. |
View RPE65 Products |
| Related Target C | PALS1 (MPP5) Direct apical complex binding partner; PDZ-domain scaffolding protein essential for polarity rescue assays. |
View PALS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large ORF exceeds single AAV packaging capacity (~4.7 kb) | Full-length CRB1 ORF Lentivirus (4.2 kb) with optimized titer for stable integration in ARPE-19 / hESC-RPE cells; compatible with dual-AAV reconstruction studies. |
| Apical membrane localization & polarity in polarized retinal cells | Anti-CRB1 recombinant antibodies validated by sequence-verified epitope mapping; C-terminal tags positioned to preserve ERLI PDZ-binding domain interactions. |
| Subfamily redundancy (CRB2/CRB3 counter-screening) | Paralog panel proteins strictly verified by mass spec; CRB2 ECD-Fc >95% purity available for selectivity assays. Ortholog panels with <40% sequence identity in extracellular regions. |
| Lack of knockdown specificity controls | Validated CRB1 siRNA included for specificity checks and rescue assay validation. |
Live CRB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CRB1 therapeutics is intensifying, driven by the urgent need to treat inherited retinal dystrophies (IRDs) such as Leber congenital amaurosis (LCA8) and retinitis pigmentosa (RP12). CRB1 is a large transmembrane protein whose coding sequence (~4.2 kb) pushes the packaging limits of standard AAV vectors (~4.7 kb). Major players—including MeiraGTx, Novartis (Luxturna model), ProQR, Editas Medicine, and Beam Therapeutics—are shifting focus from traditional single-vector gene augmentation to dual-AAV systems, mini-genes, antisense oligonucleotides (ASO), and in vivo base editing. As first-generation therapies advance toward the clinic, the next wave of R&D is targeting tropism-refined capsids, photoreceptor-versus-RPE targeting specificity, and compensatory upregulation of related proteins like CRB2 or PALS1. Subretinal delivery precision remains the critical differentiator, though intravitreal administration is an active area of innovation.
CRB1 Protein Structure & Key Mutations
CRB1 contains three extracellular EGF-like domains (EGF-like 1, EGF-like 2, EGF-like 3; UniProt P82279), which are critical for cell adhesion and polarity signaling. Pathogenic mutations in CRB1 cause inherited retinal diseases. Key missense and nonsense mutations include:
| Mutation | Associated Disease | dbSNP | Evidence |
|---|---|---|---|
| Specific substitution in RP12 | Retinitis pigmentosa 12 | rs1460946384 | UniProt VAR_064180 |
| Specific substitution in RP12 | Retinitis pigmentosa 12 | rs145141811 | UniProt VAR_067125 |
| Specific substitution in LCA8 | Leber congenital amaurosis 8 | rs62636262 | UniProt VAR_022941 |
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy (Dual‑Vector) | MeiraGTx, Novartis, Academic Consortia | LCA8, Early‑onset RP | Full‑length ORF expression & apical localization. Need lentivirus controls and localization‑grade antibodies (provided by TarMart). |
| Gene Editing (CRISPR/Base Editing) | Editas Medicine, Beam Therapeutics | Autosomal recessive RP | Mutant vs wild‑type discrimination. Need isogenic cell lines, mutant recombinant proteins, and selectivity assays. |
| RNA Therapy (Antisense Oligonucleotides) | ProQR, Ionis | Nonsense / splice‑site mutations | Minigene reporter assays. Need CRB1‑expressing stable cell lines with luciferase reporters. |
| Small Molecule (Read‑through) | Academic Translational Centers | Nonsense mutations | Functional rescue assays. Need mutant CRB1 proteins and cellular models. |